金吾财讯 | 尽管礼来(LLY)已与制药巨头达成协议，承诺在FDA宣布品牌药短缺问题解决后停止销售仿制药版本，但其远程医疗合作方仍在持续销售复配版GLP-1类减重药物。
例如过去六个月内刚与礼来建立合作关系的远程医疗平台Ro和Noom，目前二者仍在提供复配版GLP-1药物，其中甚至包括礼来竞争对手诺和诺德（Novo Nordisk，股票代码：NVO）的司美格鲁肽（semaglutide）——该药物同样在礼来此前协议的约束范围内。
对此，礼来公司发表声明强调：“任何继续销售批量复方替泽帕肽或司美格鲁肽产品的行为（包括以‘个性化’‘定制’等名义销售），均属违法行为，且严重威胁患者安全。我们将持续与监管机构协作，并采取法律手段制止此类违规销售。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.